Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer

Hartmann, Stefan; Zwick, Leonie; Maurus, Katja; Fuchs, Andreas; Brands, Roman C.; Seher, Axel; Kübler, Alexander C.; Müller‐Richter, Urs

doi:10.1016/j.jcms.2017.12.014

Cited by 8 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,21,22 Importantly, previous studies showed that MAGE-A11, a key oncoprotein correlation with poor prognosis and survival in cancer, plays crucial role in the development of HNSCC. 23,24 Hartmann et al shows that MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer. 25 We hypothesized that MAGE-A11 expression may be a predictor of malignant transformation in HNSCC.…”

Section: Discussionmentioning

confidence: 99%

<p>MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma</p>

Jia

Zhang

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancer worldwide. Growing evidence showed that Melanoma-associated antigen-A11 (MAGE-A11) was abnormally expressed in various malignancies, but MAGE-A11 expression and its biological roles in HNSCC had not been reported in detail. The aim of the study was to investigate the association between MAGE-A11 signatures and clinicopathological features of HNSCC patients and uncover its potential mechanisms in HNSCC patients. Methods: In the present study, we analyzed the expression of MAGE-A11 gene and evaluated the impact of MAGE-A11 genes expression on clinical outcome from the Cancer Genome Atlas (TCGA) database. MAGE-A11 expression was assessed in a wellcharacterized series of HNSCC (N = 75) with long-term follow-up and 10 cases of adjacent non-cancerous tissues, which were diagnosed between 2013 and 2014, by using immunohistochemistry. The correlation between MAGE-A11 expression and clinicopathological factors was analyzed. Kaplan-Meier and Cox regression analyses were used to assess the prognostic significance of MAGE-A11 expression among HNSCC patients. Results: The results showed that MAGE-A11 mRNA expression was increased in HNSCC tissues compared to "normal" tissues (P < 10 −12). MAGE-A11 protein expression was not correlated with lymph node status, relapse, age, gender, histological grade, differentiation, clinical stage, tumor size, radiotherapy or chemotherapy. The patients with high MAGE-A11 expression had lower 5-year overall survival (OS) rates than those with low MAGE-A11 expression as determined using the Kaplan-Meier method. The univariate and multivariate analyses confirmed that elevated MAGE-A11 was an independent prognostic factor for the OS of HNSCC patients. Conclusion: These findings indicate that MAGE-A11 may be a valuable diagnostic or prognostic marker as well as a potential molecular therapy target for HNSCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma</p>

Jia

Zhang

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Accumulating data proved that MAGE-A11 contributes to the genetic susceptibility and prognosis for renal cell carcinoma as a biomarker for occurrence and prognosis 43 . Besides, studies underscore that MAGE-A11 expression has a negative predictive role in head and neck cancer 44 , 45 and valuable diagnostic or prognostic marker as well as a potential molecular therapeutic target 46 . This gene not only portrays DNA hypermethylation but also is important in histone deacetylation for the mechanism underlying gene silencing in breast cancer patients 25 , 47 , 48 .…”

Section: Resultsmentioning

confidence: 99%

Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer

Mohsenzadegan

Razmi

Vafaei

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Melanoma antigen gene (MAGE)-A6 and MAGE-A11 are two of the most cancer-testis antigens overexpressed in various types of cancers. However, the clinical and prognosis value of MAGE-A6 and MAGE-A11 co-expression in the pathophysiology of the bladder is unknown. Three studies were selected from GEO databases in order to introduce the common genes that are involved in bladder cancer. Then immunohistochemical analysis for staining pattern and clinicopathological significance of suggested markers, MAGE-A6 and MAGE-A11, were performed in 199 and 213 paraffin-embedded bladder cancer with long adjacent normal tissues, respectively. A significant and positive correlation was found between both nuclear and cytoplasmic expressions of MAGE-A6 as well as expression of cytoplasmic MAGE-A11 with histological grade, PT stage, lamina propria invasion, and LP/ muscularis (L/M) involvement (all of the p-values in terms of H-score were < 0.0001). Additionally, significant differences were found between both nuclear and cytoplasmic MAGE-A6/MAGE-A11 phenotypes with tumor size (P = 0.007, P = 0.043, respectively), different histological grades, PT stage, LP involvement, and L/M involvement (all of the p-values for both phenotypes were < 0.0001). The current study added the value of these novel markers to the bladder cancer clinical settlement that might be considered as an admirable target for immunotherapy.

show abstract

“…MAGE-1 has been reported to be strongly expressed in small hepatorenal carcinoma (HCC) and exclusively in the HCC nodule 14) . Moreover, expression of the MAGE-A family in head and neck carcinoma is highly variable 15) . In our 70 cases, 43 (61.4%) strongly expressed MAGE-1 and 14 (20%) strongly expressed NY-ESO-1.…”

Section: Discussionmentioning

confidence: 99%

Expression of Cancer-testis Antigens in Adenoid Cystic Carcinoma of the Salivary Glands Correlates with Clinical Outcomes

Liang

Fang

Chen

et al. 2021

J. Hard Tissue Biology.

View full text Add to dashboard Cite

This study aimed to explore the expression and clinicopathological significance of CTAs MAGE-1, NY-ESO-1, MAGE-C2 and SCP-1 in adenoid cystic carcinoma (ACC). Immunohistochemistry was used to detect their expressions in 70 cases of ACC, and in 6 healthy tumor-adjacent salivary glands. The correlation between the expressions of the four CTAs, clinical and pathological features, and patients' overall survival (OS) were analyzed. Of the 70 ACC cases, strong staining was observed in 43 (61.4%) for MAGE-1, 14 (20%) for NY-ESO-1, 9 (12.9%) for SCP-1, and 6 (8.6%) for MAGE-C2. We also found some significant correlations between the CTAs expression and clinicopathological parameters, for example, MAGE-1 and tumor size, NY-ESO-1 and distant metastasis, MAGE-C2 and tumor site, SCP-1 and age, SCP-1 and histopathological types (P < 0.05). Patients with any single CTAs positive staining showed a similar OS compared to those with negative staining, however patients with strong expression (score 6-7) of MAGE-C2 showed a significantly reduced OS compared to those scored 0-5 (P < 0.05). There was no OS difference between patients expressing simultaneously any 2 of the 4 CTAs and those with negative expression or those expressing only one of the 2 CTAs. Similar results were found in patients expressing at least 3 CTAs compared with patients expressing less than 3 CTAs. However, patients with the four CTAs co-expression had a substantially reduced mean survival time of 131.8 months compared with 176.5 months in patients with at least one CTA negative (P < 0.05). In conclusion, a significant fraction of patients with ACC showed expression of MAGE-1, NY-ESO-1, MAGE-C2 and SCP-1, indicating these CTAs might represent potential antigens for cancer vaccines. In addition, MAGE-C2 may be an important prognostic marker of ACC.

show abstract

Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer

Cited by 8 publications

References 25 publications

<p>MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma</p>

<p>MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma</p>

Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer

Expression of Cancer-testis Antigens in Adenoid Cystic Carcinoma of the Salivary Glands Correlates with Clinical Outcomes

Contact Info

Product

Resources

About